Quay Pharma has hugely experienced analytical specialists working alongside our formulation and manufacturing teams who provide expert advice and an enormous breadth of advanced analytical capabilities.
Quay Pharma has hugely experienced analytical specialists working alongside our formulation and manufacturing teams who provide expert advice and an enormous breadth of advanced analytical capabilities. Their contribution is vital in our success in early-stage formulation development, stability studies, and clinical trial manufacture.
Analytical Services Include:
Analytical method transfer, development and validation.
Stability-indicating assays using UPLC and HPLC (including forced degradation studies).
Formal and informal stability study design, storage and testing.
Batch release and raw material testing.
Chemical and physical testing.
Dissolution testing and drug release profiling.
Drug substance characterisation.
The identification and quantification of impurities.
Testing of raw materials to ensure that each formulation component meets our quality requirements.
In-process assays to establish that the manufacturing processes are meeting the standards set out in advance.
Carrying out of final product assays to verify that product meets its specification.
We employ stability testing to evaluate the useful shelf life of the product.
Your Dedicated Contacts
Head of Business Development (Formulation Development)
Maura McArdle joined Quay as Head of Business Development for Europe in 2019. Maura’s appointment is to ensure continued focus on Quay’s core business, Pharmaceutical Development of small molecule compounds. With a degree in Chemical Engineering, Maura has over 20 years of business development experience into the Chemical and Pharmaceutical industries having previously worked for Almac, Brenntag and BASF.
Mike has over 20 years’ experience in drug product development. For over 15 years he has been responsible for development activities at Quay Pharma. During this period Mike has overseen over 200 non-sterile development projects; predominantly taking NCE’s through to first in human studies and beyond. His background is in formulation science with a PhD in liquisolid dosage forms and is cited as an inventor on multiple oral formulation patents.